DVAX
HealthcareDynavax Technologies Corporation
$15.41
+$0.03 (+0.20%)
Jan 5, 2026
Price History (1Y)
Analysis
Dynavax Technologies Corporation is a publicly traded company in the healthcare sector, specifically within the drug manufacturers - specialty & generic industry. With a market capitalization of $1.81B, the company has a significant scale, accompanied by revenue of $330.51M and approximately 405 employees. From a financial health perspective, Dynavax exhibits mixed results. The company's gross margin is 61.6%, while its operating margin stands at 24.8%. However, the profit margin is negative at -13.1%. Regarding returns on equity and assets, Dynavax reports a return on equity of -7.1% and a return on assets of 1.2%. Its balance sheet features a debt-to-equity ratio of 54.15 and cash holdings of $647.81M against total debt of $289.22M. In terms of valuation, the company's forward P/E is 46.70, with revenue growth at 17.7% year-over-year and earnings growth at 69.3%. The price to book ratio stands at 3.39 and the price to sales ratio is 5.47. Notably, the dividend yield is not applicable, as indicated by a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Visit website →Key Statistics
- Market Cap
- $1.81B
- P/E Ratio
- N/A
- 52-Week High
- $15.49
- 52-Week Low
- $9.20
- Avg Volume
- 2.39M
- Beta
- 0.89
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 405